The long standing Hematology T32 Training Grant at the University of North Carolina at Chapel Hill (UNC-CH) remains committed to training both MD physician-scientists and PhD scientists for careers in academic hematology and hematology research. This program will continue to train adult and pediatric hematology fellows and PhD post- doctoral candidates in areas of traditional institutional research strengths encompassing benign hematology. Both basic bench and clinical research tracks are available, with carefully selected didactic coursework to complement the training experience. In this competitive renewal application, scientific and educational interactions between MD and PhD trainees in the form of conferences, journal clubs, and symposia have been emphasized. Following 2 years of training on the T32 grant, trainees will be encouraged to apply for individual or institutional K series awards, and/or other sources of independent funding.

Public Health Relevance

For over 35 years, the training program in academic hematology at the University of North Carolina at Chapel Hill (UNC-CH) has benefitted from support by the Ruth L. Kirschstein National Research Service Award. This program, which encompasses disorders of the blood, vasculature or immune system, has been extraordinarily successful in its mission to train clinical and bench researchers in hematology. The cornerstones of training include a mentored research project, focused seminars and conferences, training in the responsible conduct of research, and didactic coursework in clinical research, laboratory methodology, grantsmanship, and the academic community. Both MD and PhD postdoctoral candidates are recruited from intramural and extramural sources, and their frequent interaction during the 2-year period of support engenders a mutual respect and understanding of the ultimate goals of biomedical research in hematologic disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007149-38
Application #
8680284
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Mondoro, Traci
Project Start
1975-07-01
Project End
2017-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
38
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Hisada, Yohei; Thålin, Charlotte; Lundström, Staffan et al. (2018) Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients. Thromb Res 165:1-5
Beckman, Joan D; Kasthuri, Raj S; Wolberg, Alisa S et al. (2018) Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors. Haemophilia 24:e417-e420
Klein, Mia; Chang, Alicia K; Vasudevan, Sanjeev A et al. (2018) Clinically significant ascites as an indication for resection of rapidly involuting congenital hepatic hemangiomas. Pediatr Blood Cancer 65:e27222
Beckman, Joan D; Rollins-Raval, Marian A; Raval, Jay S et al. (2018) Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. Am J Ther 25:e270-e272
Beckman, J D; Holle, L A; Wolberg, A S (2018) Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin ?-chain crosslinking. J Thromb Haemost 16:131-141
Hisada, Yohei; Mackman, Nigel (2018) Mouse models of cancer-associated thrombosis. Thromb Res 164 Suppl 1:S48-S53
Pahl, Kristy S; Kim, Kyung; Sams, Casey et al. (2018) Inconsistency in classifying vascular anomalies: What's in a name? Pediatr Blood Cancer 65:
Lee, Robert H; Piatt, Raymond; Conley, Pamela B et al. (2017) Effects of ibrutinib treatment on murine platelet function during inflammation and in primary hemostasis. Haematologica 102:e89-e92
Noubouossie, Denis F; Whelihan, Matthew F; Yu, Yuan-Bin et al. (2017) In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood 129:1021-1029
Croteau, S E; Abajas, Y L; Wolberg, A S et al. (2017) Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor. Haemophilia 23:e93-e98

Showing the most recent 10 out of 72 publications